Research programme: antibody therapeutics and diagnostics - MorphoSys/Bayer ScheringAlternative Names: Antibody therapeutics and diagnostics research programme - MorphoSys/Schering
Latest Information Update: 24 Mar 2010
At a glance
- Originator Bayer Schering Pharma; MorphoSys
- Developer Bayer HealthCare Pharmaceuticals; MorphoSys
- Class Antibodies; Antibody diagnostics
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Aug 2003 Preclinical trials in Cancer in Germany (unspecified route)
- 13 Mar 2002 Preclinical trials in Cancer diagnosis in Germany (unspecified route)